Date: 2015-11-04
Type of information: Construction of a production plant
Compound: new insulin filling facility in Denmark
Company: Novo Nordisk (Denmark)
Therapeutic area: Metabolic diseases
Type agreement: construction of a production plant
Action mechanism:
Disease: diabetes, obesity
Details: * On November 4, 2015, Novo Nordisk announced that the group is investing 2.1 billion Danish kroner in a new 10,300 m2 facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity.
A groundbreaking ceremony marking the start of construction has been held on Wednesday 4 November, at the company's Hillerød site, attended by the mayor of Hillerød, Dorte Meldgaard.
The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people. Incorporating the latest state-of-the-art insulin production technology, the new insulin filling facility will ensure production capacity for existing and future products within diabetes. Established in 1992, the Hillerød site covers an area of about 1,650,000 m2, of which 90,000 m2 is used for production, research and development. The site houses a facility for device R&D and three production facilities: one for moulding and pre-assembly of components, one for filling, assembly and packaging of diabetes finished products and one for the production of active pharmaceutical ingredients for haemophilia products.
Financial terms:
Latest news:
